Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation

Search Page

Filters

My Custom Filters

Publication date

Text availability

Article attribute

Article type

Additional filters

Article Language

Species

Sex

Age

Other

Search Results

4,344 results

Filters applied: . Clear all
Results are displayed in a computed author sort order. The Publication Date timeline is not available.
Page 1
Safety and efficacy of tisagenlecleucel in patients with relapsed or refractory B-cell lymphoma: the first real-world evidence in Japan.
Goto H, Kitawaki T, Fujii N, Kato K, Onishi Y, Fukuhara N, Yamauchi T, Toratani K, Kobayashi H, Yoshida S, Shimo M, Onodera K, Senjo H, Onozawa M, Hirata K, Yokota I, Teshima T. Goto H, et al. Among authors: hirata k. Int J Clin Oncol. 2023 Jun;28(6):816-826. doi: 10.1007/s10147-023-02334-w. Epub 2023 Apr 18. Int J Clin Oncol. 2023. PMID: 37071252
Serum level of soluble interleukin-2 receptor is positively correlated with metabolic tumor volume on 18 F-FDG PET/CT in newly diagnosed patients with diffuse large B-cell lymphoma.
Senjo H, Kanaya M, Izumiyama K, Minauchi K, Hirata K, Mori A, Saito M, Tanaka M, Iijima H, Tsukamoto E, Itoh K, Ota S, Morioka M, Hashimoto D, Teshima T; North Japan Hematology Study Group (NJHSG). Senjo H, et al. Among authors: hirata k. Cancer Med. 2019 Mar;8(3):953-962. doi: 10.1002/cam4.1973. Epub 2019 Feb 20. Cancer Med. 2019. PMID: 30790452 Free PMC article.
High metabolic heterogeneity on baseline 18FDG-PET/CT scan as a poor prognostic factor for newly diagnosed diffuse large B-cell lymphoma.
Senjo H, Hirata K, Izumiyama K, Minauchi K, Tsukamoto E, Itoh K, Kanaya M, Mori A, Ota S, Hashimoto D, Teshima T; North Japan Hematology Study Group. Senjo H, et al. Among authors: hirata k. Blood Adv. 2020 May 26;4(10):2286-2296. doi: 10.1182/bloodadvances.2020001816. Blood Adv. 2020. PMID: 32453838 Free PMC article.
Reoxygenation of glioblastoma multiforme treated with fractionated radiotherapy concomitant with temozolomide: changes defined by 18F-fluoromisonidazole positron emission tomography: two case reports.
Narita T, Aoyama H, Hirata K, Onodera S, Shiga T, Kobayashi H, Murata J, Terasaka S, Tanaka S, Houkin K. Narita T, et al. Among authors: hirata k. Jpn J Clin Oncol. 2012 Feb;42(2):120-3. doi: 10.1093/jjco/hyr181. Epub 2011 Dec 23. Jpn J Clin Oncol. 2012. PMID: 22198964
The prognostic improvement of add-on bevacizumab for progressive disease during concomitant temozolomide and radiation therapy in patients with glioblastoma and anaplastic astrocytoma.
Yamaguchi S, Ishi Y, Motegi H, Okamoto M, Kobayashi H, Hirata K, Oda Y, Tanaka S, Terasaka S, Houkin K. Yamaguchi S, et al. Among authors: hirata k. J Neurosurg Sci. 2020 Dec;64(6):502-508. doi: 10.23736/S0390-5616.18.04463-6. Epub 2018 Jul 9. J Neurosurg Sci. 2020. PMID: 30035459 Free article.
4,344 results